famotidine has been researched along with Esophagitis in 11 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Esophagitis: INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine is effective in the prevention of gastric and duodenal ulcers, and erosive oesophagitis in patients taking low-dose aspirin." | 9.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "This US multicentre, randomized, double-blind, placebo-controlled, parallel group study determined the effects of two twice daily oral famotidine regimens on symptom relief and healing of erosive oesophagitis in patients with gastro-oesophageal reflux disease." | 9.07 | Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. ( Berenson, MM; Berlin, RG; Cagliola, A; Simon, TJ; Snapinn, S, 1994) |
| "Forty-four patients with esophagitis refractory to standard H2-blocker therapy, who had healed after a 4- to 16-wk course with either 20-40 mg omeprazole or ranitidine at doses of 300-600 mg daily in a randomized double-blind study, commenced a 3-month maintenance course of therapy with 40 mg bid famotidine." | 9.07 | High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study. ( Bianchi-Porro, G; Bonavina, L; Pace, F; Peracchia, A; Sangaletti, O; Termini, R; Vigneri, S, 1991) |
| " Most studies have documented the need for multiple daily dosing with H2-antagonists to achieve clinical and statistical efficacy for symptom relief." | 6.67 | Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group. ( Barden, P; Decktor, DL; Holt, S; Hufnagel, K; Humphries, TJ; Moyer, R; Pevelery, M; Robinsen, M; Root, J; Stone, RC, 1991) |
| "Famotidine is effective in the prevention of gastric and duodenal ulcers, and erosive oesophagitis in patients taking low-dose aspirin." | 5.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "This US multicentre, randomized, double-blind, placebo-controlled, parallel group study determined the effects of two twice daily oral famotidine regimens on symptom relief and healing of erosive oesophagitis in patients with gastro-oesophageal reflux disease." | 5.07 | Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. ( Berenson, MM; Berlin, RG; Cagliola, A; Simon, TJ; Snapinn, S, 1994) |
| "Forty-four patients with esophagitis refractory to standard H2-blocker therapy, who had healed after a 4- to 16-wk course with either 20-40 mg omeprazole or ranitidine at doses of 300-600 mg daily in a randomized double-blind study, commenced a 3-month maintenance course of therapy with 40 mg bid famotidine." | 5.07 | High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study. ( Bianchi-Porro, G; Bonavina, L; Pace, F; Peracchia, A; Sangaletti, O; Termini, R; Vigneri, S, 1991) |
| "Twenty-four-hour gastric and esophageal pH were monitored simultaneously in 19 patients with moderate esophagitis before and after a randomized crossover treatment with 40 mg famotidine or 300 mg ranitidine." | 5.06 | Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis. ( Abbritti, F; Fiorucci, S; Morelli, A; Perrone, E; Santucci, L, 1989) |
| "In an open clinical endoscopically controlled study in 30 consecutive patients with rheumatic diseases complicated by the ulcerative and erosive form of gastroduodenopathy induced by non-steroidal antiinflammatory drugs and oesophagitis, after four weeks treatment with oral famotidine (one dose of 40 mg/day) confirmed a significant improvement of the mean oesophageal (0." | 3.69 | [Famotidine in the treatment of gastropathy induced by non-steroidal antirheumatic agents]. ( Hyrdel, R; Rovenský, J; Rybár, I, 1997) |
| " Most studies have documented the need for multiple daily dosing with H2-antagonists to achieve clinical and statistical efficacy for symptom relief." | 2.67 | Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group. ( Barden, P; Decktor, DL; Holt, S; Hufnagel, K; Humphries, TJ; Moyer, R; Pevelery, M; Robinsen, M; Root, J; Stone, RC, 1991) |
| "The majority of gastro-oesophageal reflux disease (GERD) seems to be non-erosive reflux disease." | 1.33 | Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. ( Hiraishi, H; Masuyama, H; Nakamura, T; Shirakawa, K; Sugaya, H; Terano, A, 2005) |
| "Oesophagitis was induced by pyloric ligation in wild-type and VR-1 deficient mice." | 1.33 | Attenuation of acid induced oesophagitis in VR-1 deficient mice. ( de la Fuente, SG; Fujino, K; Mantyh, CR; Takahashi, T; Takami, Y, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hawkey, CJ | 1 |
| Taha, AS | 1 |
| McCloskey, C | 1 |
| Prasad, R | 1 |
| Bezlyak, V | 1 |
| Nakamura, T | 1 |
| Shirakawa, K | 1 |
| Masuyama, H | 1 |
| Sugaya, H | 1 |
| Hiraishi, H | 1 |
| Terano, A | 1 |
| Fujino, K | 1 |
| de la Fuente, SG | 1 |
| Takami, Y | 1 |
| Takahashi, T | 1 |
| Mantyh, CR | 1 |
| Turton, DB | 1 |
| Shakir, KM | 1 |
| Ducrotté, P | 1 |
| Guillemot, F | 1 |
| Elouaer-Blanc, L | 1 |
| Hirschauer, C | 1 |
| Thorel, JM | 1 |
| Petit, A | 1 |
| Hochain, P | 1 |
| Michel, P | 1 |
| Cortot, A | 1 |
| Colin, R | 1 |
| Simon, TJ | 1 |
| Berenson, MM | 1 |
| Berlin, RG | 1 |
| Snapinn, S | 1 |
| Cagliola, A | 1 |
| Rybár, I | 1 |
| Rovenský, J | 1 |
| Hyrdel, R | 1 |
| Robinsen, M | 1 |
| Decktor, DL | 1 |
| Stone, RC | 1 |
| Pevelery, M | 1 |
| Barden, P | 1 |
| Moyer, R | 1 |
| Holt, S | 1 |
| Root, J | 1 |
| Hufnagel, K | 1 |
| Humphries, TJ | 1 |
| Bianchi-Porro, G | 1 |
| Pace, F | 1 |
| Sangaletti, O | 1 |
| Peracchia, A | 1 |
| Bonavina, L | 1 |
| Vigneri, S | 1 |
| Termini, R | 1 |
| Fiorucci, S | 1 |
| Santucci, L | 1 |
| Perrone, E | 1 |
| Abbritti, F | 1 |
| Morelli, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
5 trials available for famotidine and Esophagitis
| Article | Year |
|---|---|
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Double-Blind Me | 2009 |
Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis.
Topics: Administration, Oral; Adult; Double-Blind Method; Esophagitis; Famotidine; Female; Gastroesophageal | 1994 |
Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group.
Topics: Administration, Oral; Adult; Antacids; Double-Blind Method; Drug Administration Schedule; Esophagiti | 1991 |
High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study.
Topics: Adult; Double-Blind Method; Esophagitis; Esophagoscopy; Famotidine; Female; Humans; Male; Middle Age | 1991 |
Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Esophagitis; Esophagus; Famotidine; Fema | 1989 |
6 other studies available for famotidine and Esophagitis
| Article | Year |
|---|---|
NSAIDs and aspirin: notorious or FAMOUS?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase Inhibitors; Esop | 2009 |
Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Bile; Color; Esophagitis; Esophagoscopy; Famotidine; Female; Gastrit | 2005 |
Attenuation of acid induced oesophagitis in VR-1 deficient mice.
Topics: Acute Disease; Animals; Anti-Ulcer Agents; Capsaicin; Endocytosis; Esophagitis; Famotidine; Hydrogen | 2006 |
Galactorrhea caused by esophagitis.
Topics: Adult; Anti-Ulcer Agents; Bethanechol; Esophagitis; Famotidine; Female; Galactorrhea; Gastroesophage | 1995 |
Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: a cross-over study.
Topics: Adult; Aged; Esophagitis; Esophagus; Famotidine; Female; Gastric Acid; Gastroesophageal Reflux; Huma | 1994 |
[Famotidine in the treatment of gastropathy induced by non-steroidal antirheumatic agents].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Esophagitis; Famotidine; Female; Histamine H2 Antagonists; | 1997 |